TSLA
Tesla
-- 462.280 NVDA
NVIDIA
-- 140.220 PLTR
Palantir
-- 82.380 MSTR
MicroStrategy
-- 358.180 AMD
Advanced Micro Devices
-- 126.290 
NEWS
Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting
Jaguar Health (NASDAQ:JAGX) announced positive results from two independent investigator-initiated studies of crofelemer, presented at the American College of Gastroenterology Annual Scientific Meeting. The first study showed that crofelemer significantly decreased stool consistency and abdominal pain in patients with functional diarrhea. The second study demonstrated that 58.8% of patients with chronic idiopathic diarrhea improved within a 4-week treatment period. Both studies suggest crofelemer's effectiveness in treating different forms of chronic diarrhea, with minimal side effects. The drug has also shown promise in previous Phase 2 trials for IBS-D and achieved statistical significance in breast cancer patients from the Phase 3 OnTarget trial.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Moooolah :
Moooolah : Dr Jag's company. kidding![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")